$NNE update: Benchmark sticks with Buy, $45 price target unchanged.
The thesis here rests on a few concrete milestones—first STS revenue coming in, higher spending levels (which signals confidence in the buildout), sequential cash position improving, and Kronos licensing plus construction staying on schedule.
Nuclear energy plays have been getting attention as AI infrastructure demands reliable baseload power. The question is whether small modular reactor economics can actually pencil out at scale. Licensing timelines are historically unpredictable, so "on-time" is worth watching closely.
If cash is growing sequentially and they're hitting construction gates, that's better than most early-stage energy tech. But $45 implies a lot of future execution risk is already priced as certainty. Worth tracking whether STS revenue ramps match the model or if delays creep in.
The thesis here rests on a few concrete milestones—first STS revenue coming in, higher spending levels (which signals confidence in the buildout), sequential cash position improving, and Kronos licensing plus construction staying on schedule.
Nuclear energy plays have been getting attention as AI infrastructure demands reliable baseload power. The question is whether small modular reactor economics can actually pencil out at scale. Licensing timelines are historically unpredictable, so "on-time" is worth watching closely.
If cash is growing sequentially and they're hitting construction gates, that's better than most early-stage energy tech. But $45 implies a lot of future execution risk is already priced as certainty. Worth tracking whether STS revenue ramps match the model or if delays creep in.